Advertisement

A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer

  • Lu Cao
  • Guomin Xiang
  • Fang Liu
  • Cong Xu
  • Jing Liu
  • Qingxiang Meng
  • Shuhua Lyu
  • Shuling Wang
  • Yun NiuEmail author
Original Article
  • 2 Downloads

Abstract

Purpose

Approximately 30% oestrogen receptor alpha (ERα)-positive breast cancer (BC) patients exhibit intrinsic or recurrent resistance to adjuvant endocrine therapy with tamoxifen. The androgen receptor (AR) is expressed in about 90% of ERα-positive patients, with particularly high expression in tamoxifen-resistant tumours. Prostate-derived Ets factor (PDEF), which is a co-regulator of AR, plays a role in tamoxifen resistance in ERα-positive BC. The purpose of this research was to analyse the potential roles of AR, PDEF and ERα levels in the response to tamoxifen resistance in ERα-positive BC.

Methods

The nuclear AR:ERα and PDEF:ERα ratios were examined immunohistochemically in a cohort of 225 ERα-positive pre-menopausal BC patients who had received adjuvant tamoxifen therapy.

Results

For both AR:ERα and PDEF:ERα ratios, the optimal cutoff value was 2.0. Patients receiving adjuvant tamoxifen treatment who had a high AR:ERα (≥ 2.0) (HR = 3.90) or PDEF:ERα ratio (≥ 2.0) (HR = 2.77) had a beyond twofold increased risk of failure. Both the AR:ERα ratio (P = 0.001) and PDEF:ERα ratio (P = 0.002) were independently associated with the risk of tamoxifen treatment failure. Furthermore, both a high ratio of AR:ERα (≥ 2.0) and PDEF:ERα (≥ 2.0) were associated with shorter disease-free survival (DFS) and shorter disease-specific survival (DSS). In addition, both the AR:ERα ratio and PDEF:ERα ratio were independent predictors of DFS (both P < 0.0001) and DSS (P = 0.001 and P < 0.0001, respectively).

Conclusions

AR:ERα and PDEF:ERα ratios are independent predictors of the response to conventional ERα-directed tamoxifen endocrine therapy.

Keywords

Prostate-derived Ets factor Androgen receptor Oestrogen receptor alpha Tamoxifen Breast cancer 

Notes

Acknowledgements

We thank the BC patients and their families. They generously donated valuable tissue samples.

Funding

This study was funded by National Natural Science Foundation of China (Grant Numbers 81172532, 81602340).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Riggs BL, Hartmann LC (2003) Selective estrogen-receptor modulators—mechanisms of action and application to clinical practice. N Engl J Med 348(7):618–629.  https://doi.org/10.1056/NEJMra022219 Google Scholar
  2. 2.
    Patel HK, Bihani T (2018) Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol Ther 186:1–24.  https://doi.org/10.1016/j.pharmthera.2017.12.012 Google Scholar
  3. 3.
    An KC (2016) Selective estrogen receptor modulators. Asian Spine J 10(4):787–791.  https://doi.org/10.4184/asj.2016.10.4.787 PubMedCentralGoogle Scholar
  4. 4.
    Ali S, Rasool M, Chaoudhry H, Pushparaj PN, Jha P, Hafiz A, Mahfooz M, Abdus Sami G, Azhar Kamal M, Bashir S, Ali A, Sarwar Jamal M (2016) Molecular mechanisms and mode of tamoxifen resistance in breast cancer. Bioinformation 12(3):135–139.  https://doi.org/10.6026/97320630012135 PubMedCentralGoogle Scholar
  5. 5.
    Ekpo EU, Brennan PC, Mello-Thoms C, McEntee MF (2016) Relationship between breast density and selective estrogen-receptor modulators, aromatase inhibitors, physical activity, and diet: a systematic review. Integr Cancer Ther 15(2):127–144.  https://doi.org/10.1177/1534735416628343 PubMedCentralGoogle Scholar
  6. 6.
    Jordan VC (2014) Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocr Relat Cancer 21(3):R235–R246.  https://doi.org/10.1530/ERC-14-0092 PubMedCentralGoogle Scholar
  7. 7.
    Ang WC, Farrell E, Vollenhoven B (2001) Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review. Climact J Int Menopause Soc 4(4):284–292Google Scholar
  8. 8.
    Xu B, Lovre D, Mauvais-Jarvis F (2016) Effect of selective estrogen receptor modulators on metabolic homeostasis. Biochimie 124:92–97.  https://doi.org/10.1016/j.biochi.2015.06.018 Google Scholar
  9. 9.
    Abdel-Hafiz HA (2017) Epigenetic mechanisms of tamoxifen resistance in luminal breast cancer. Diseases.  https://doi.org/10.3390/diseases5030016 PubMedCentralGoogle Scholar
  10. 10.
    Sharma D, Kumar S, Narasimhan B (2018) Estrogen alpha receptor antagonists for the treatment of breast cancer: a review. Chem Cent J 12(1):107.  https://doi.org/10.1186/s13065-018-0472-8 Google Scholar
  11. 11.
    Siersbaek R, Kumar S, Carroll JS (2018) Signaling pathways and steroid receptors modulating estrogen receptor alpha function in breast cancer. Genes Dev 32(17–18):1141–1154.  https://doi.org/10.1101/gad.316646.118 PubMedCentralGoogle Scholar
  12. 12.
    Li F, Dou J, Wei L, Li S, Liu J (2016) The selective estrogen receptor modulators in breast cancer prevention. Cancer Chemother Pharmacol 77(5):895–903.  https://doi.org/10.1007/s00280-016-2959-0 Google Scholar
  13. 13.
    Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, MacGrogan G, Lerebours F, Finetti P, Longy M, Bertheau P, Bertrand F, Bonnet F, Martin AL, Feugeas JP, Bieche I, Lehmann-Che J, Lidereau R, Birnbaum D, Bertucci F, de The H, Theillet C (2012) A refined molecular taxonomy of breast cancer. Oncogene 31(9):1196–1206.  https://doi.org/10.1038/onc.2011.301 Google Scholar
  14. 14.
    Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM (2011) Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol 24(7):924–931.  https://doi.org/10.1038/modpathol.2011.54 PubMedCentralGoogle Scholar
  15. 15.
    Wu Y, Vadgama JV (2017) Androgen receptor as a potential target for treatment of breast cancer. Int J Cancer Res Mol Mech.  https://doi.org/10.16966/2381-3318.129 Google Scholar
  16. 16.
    Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, Carroll JS (2011) Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J 30(15):3019–3027.  https://doi.org/10.1038/emboj.2011.216 PubMedCentralGoogle Scholar
  17. 17.
    Elebro K, Bendahl PO, Jernstrom H, Borgquist S (2017) Androgen receptor expression and breast cancer mortality in a population-based prospective cohort. Breast Cancer Res Treat 165(3):645–657.  https://doi.org/10.1007/s10549-017-4343-0 PubMedCentralGoogle Scholar
  18. 18.
    Jiang HS, Kuang XY, Sun WL, Xu Y, Zheng YZ, Liu YR, Lang GT, Qiao F, Hu X, Shao ZM (2016) Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status. Oncotarget 7(27):41285–41293.  https://doi.org/10.18632/oncotarget.9778 PubMedCentralGoogle Scholar
  19. 19.
    Kono M, Fujii T, Lim B, Karuturi MS, Tripathy D, Ueno NT (2017) Androgen receptor function and androgen receptor-targeted therapies in breast cancer: a review. JAMA Oncol 3(9):1266–1273.  https://doi.org/10.1001/jamaoncol.2016.4975 Google Scholar
  20. 20.
    Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, Marotti JD, Hankinson SE, Colditz GA, Tamimi RM (2011) Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 17(7):1867–1874.  https://doi.org/10.1158/1078-0432.CCR-10-2021 PubMedCentralGoogle Scholar
  21. 21.
    Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A (2010) Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 124(3):607–617.  https://doi.org/10.1007/s10549-010-0761-y Google Scholar
  22. 22.
    Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE, Nicholson RI (2003) Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 81(1):81–93.  https://doi.org/10.1023/A:1025484908380 Google Scholar
  23. 23.
    De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT, Chamness GC, Hilsenbeck SG, Ando S, Fuqua SA (2010) Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat 121(1):1–11.  https://doi.org/10.1007/s10549-009-0436-8 Google Scholar
  24. 24.
    Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D’Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gomez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK (2014) Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res BCR 16(1):R7.  https://doi.org/10.1186/bcr3599 Google Scholar
  25. 25.
    Gunawardane RN, Sgroi DC, Wrobel CN, Koh E, Daley GQ, Brugge JS (2005) Novel role for PDEF in epithelial cell migration and invasion. Cancer Res 65(24):11572–11580.  https://doi.org/10.1158/0008-5472.CAN-05-1196 PubMedCentralGoogle Scholar
  26. 26.
    Mahajan N (2016) Signatures of prostate-derived Ets factor (PDEF) in cancer. Tumour Biol.  https://doi.org/10.1007/s13277-016-5326-1 Google Scholar
  27. 27.
    Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, Grall F, Dube A, Weiss A, Brown L, Quinn G, Kas K, Endress G, Kunsch C, Libermann TA (2000) PDEF, a novel prostate epithelium-specific Ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biolo Chem 275(2):1216–1225Google Scholar
  28. 28.
    Cao L, Li C, Xu C, Xiang G, Liu F, Liu X, Jiao J, Lv S, Niu Y (2018) Clinical significance of PDEF factor expression and its relation to androgen receptor in ER(-) breast cancer. Histopathology.  https://doi.org/10.1111/his.13699 Google Scholar
  29. 29.
    Cao L, Xu C, Xiang G, Liu F, Liu X, Li C, Liu J, Meng Q, Jiao J, Niu Y (2018) AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer. Mol Cancer 17(1):136.  https://doi.org/10.1186/s12943-018-0883-0 PubMedCentralGoogle Scholar
  30. 30.
    Buchwalter G, Hickey MM, Cromer A, Selfors LM, Gunawardane RN, Frishman J, Jeselsohn R, Lim E, Chi D, Fu X, Schiff R, Brown M, Brugge JS (2013) PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells. Cancer Cell 23(6):753–767.  https://doi.org/10.1016/j.ccr.2013.04.026 PubMedCentralGoogle Scholar
  31. 31.
    Cao L, Qi L, Zhang L, Song W, Yu Y, Xu C, Li L, Guo Y, Yang L, Liu C, Huang Q, Wang Y, Sun B, Meng B, Zhang B, Cao W (2017) Human nonsense-mediated RNA decay regulates EMT by targeting the TGF-ss signaling pathway in lung adenocarcinoma. Cancer Lett 403:246–259.  https://doi.org/10.1016/j.canlet.2017.06.021 Google Scholar
  32. 32.
    Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, Lee KS (2010) Expression of androgen receptors in primary breast cancer. Ann Oncol 21(3):488–492.  https://doi.org/10.1093/annonc/mdp510 Google Scholar
  33. 33.
    Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL, Henshall SM, Birrell SN, Coetzee GA, Sutherland RL, Butler LM, Tilley WD (2009) Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 69(15):6131–6140.  https://doi.org/10.1158/0008-5472.CAN-09-0452 Google Scholar
  34. 34.
    Panet-Raymond V, Gottlieb B, Beitel LK, Pinsky L, Trifiro MA (2000) Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol 167(1–2):139–150Google Scholar
  35. 35.
    Pietri E, Conteduca V, Andreis D, Massa I, Melegari E, Sarti S, Cecconetto L, Schirone A, Bravaccini S, Serra P, Fedeli A, Maltoni R, Amadori D, De Giorgi U, Rocca A (2016) Androgen receptor signaling pathways as a target for breast cancer treatment. Endocr Relat Cancer 23(10):R485–R498.  https://doi.org/10.1530/ERC-16-0190 Google Scholar
  36. 36.
    Rizza P, Barone I, Zito D, Giordano F, Lanzino M, De Amicis F, Mauro L, Sisci D, Catalano S, Dahlman Wright K, Gustafsson JA, Ando S (2014) Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines. Breast Cancer Res BCR 16(1):R21.  https://doi.org/10.1186/bcr3619 Google Scholar
  37. 37.
    Lim E, Ni M, Cao S, Hazra A, Tamimi RM, Brown M (2014) Importance of breast cancer subtype in the development of androgen receptor directed therapy. Curr Breast Cancer Report 6(2):71–78.  https://doi.org/10.1007/s12609-014-0140-5 Google Scholar
  38. 38.
    Ghadersohi A, Sood AK (2001) Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. Clin Cancer Res 7(9):2731–2738Google Scholar
  39. 39.
    Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK (2003) Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 63(15):4626–4631Google Scholar
  40. 40.
    Feldman RJ, Sementchenko VI, Watson DK (2003) The epithelial-specific Ets factors occupy a unique position in defining epithelial proliferation, differentiation and carcinogenesis. Anticancer Res 23(3A):2125–2131Google Scholar
  41. 41.
    Viedma-Rodriguez R, Baiza-Gutman L, Salamanca-Gomez F, Diaz-Zaragoza M, Martinez-Hernandez G, Ruiz Esparza-Garrido R, Velazquez-Flores MA, Arenas-Aranda D (2014) Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review). Oncol Rep 32(1):3–15.  https://doi.org/10.3892/or.2014.3190 Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Breast Cancer Pathology and Research Laboratory, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Ministry of EducationTianjin Medical University Cancer Institute and Hospital, Tianjin Medical UniversityTianjinChina
  2. 2.Department of Pathology, Tianjin Union Medical CenterTianjin People’s HospitalTianjinChina
  3. 3.Department of Breast Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Ministry of EducationTianjin Medical University Cancer Institute and Hospital, Tianjin Medical UniversityTianjinChina

Personalised recommendations